6531 |
SOLUTE CARRIER FAMILY 6 MEMBER 3 |
SLC6A3 |
DAT |
DAT1 |
PKDYS |
126455 |
11049 |
ENSG00000142319 |
OTTHUMG00000131016 |
DA TRANSPORTER |
Q01959 |
SODIUM-DEPENDENT DOPAMINE TRANSPORTER |
DOPAMINE TRANSPORTER |
SC6A3_HUMAN |
SODIUM-DEPENDENT DOPAMINE TRANSPORTER (DA TRANSPORTER) (DAT). [SOURCE:UNIPROT/SWISSPROT;ACC:Q01959] |
PA311 |
T55959 |
PKDYS1 |
Uniprot Status | Swiss-Prot |
Interpro Name | Sodium:neurotransmitter symporter |
Interpro Acc | IPR000175 |
Interpro Type | Family |
Human Readable Name | TRANSPORTER |
Uniprot Evidence | 1: Evidence at protein level |
Interpro Short Name | Na/ntran_symport |
Human Readable Name | DRUGGABLE GENOME |
Target Class | Transporters |
Target Subclass | TC:2.A.22.1.3 |
Target Subclass | SLC |
Transmembrane Helix Count | 12 |
Target Subclass | SLC6 |
Target Main Class | Transporters |
Target Subclass | Other |
Gene Biotype | PROTEIN_CODING |
TRANSPORTER |
CELL SURFACE |
DRUGGABLE GENOME |
inhibitor (inhibitory) |
Trial Name | - |
Novel drug target | Established target |
n/a |
Trial Name | altropane |
Novel drug target | Established target |
inhibitor (inhibitory) |
Trial Name | - |
Novel drug target | Established target |
antagonist (inhibitory) |
inhibitor (inhibitory) |
Mechanism of Interaction | Dopamine transporter inhibitor |
Direct Interaction | yes |
Trial Name | armodafinil, R-modafinil,Nuvigil |
inhibitor (inhibitory) |
Trial Name | - |
Novel drug target | Established target |
negative modulator (inhibitory) |
inhibitor (inhibitory) |
Trial Name | SLI 381, SPD 465,Adderall, Adderall XR, Adderall IR |
Novel drug target | Established target |
Direct Interaction | yes |
negative modulator (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Dopamine transporter releasing agent |
Trial Name | SLI 381, SPD 465,Adderall, Adderall XR, Adderall IR |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Dopamine transporter inhibitor |
Trial Name | modafinil,Provigil, Sparlon |
inhibitor (inhibitory) |
Trial Name | - |
Novel drug target | Established target |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Monoamine transporter inhibitor |
n/a |
Trial Name | - |
Novel drug target | Established target |
n/a |
Trial Name | Vyvanse |
Novel drug target | Established target |
Mechanism of Interaction | Dopamine transporter releasing agent |
inhibitor (inhibitory) |
Mechanism of Interaction | Dopamine transporter inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Dopamine transporter inhibitor |
Direct Interaction | yes |
n/a |
Mechanism of Interaction | Dopamine transporter releasing agent |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Dopamine transporter inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Dopamine transporter inhibitor |
Direct Interaction | yes |
n/a |
Mechanism of Interaction | Dopamine transporter releasing agent |
Direct Interaction | yes |
n/a |
Direct Interaction | yes |
Mechanism of Interaction | Dopamine transporter releasing agent |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Dopamine transporter inhibitor |
inhibitor (inhibitory) |
Mechanism of Interaction | Dopamine transporter inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Dopamine transporter inhibitor |
Direct Interaction | yes |
Trial Name | Daytrana |
inhibitor (inhibitory) |
Mechanism of Interaction | Monoamine transporter inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Dopamine transporter inhibitor |
Direct Interaction | yes |
n/a |
Mechanism of Interaction | Dopamine transporter releasing agent |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Monoamine transporter inhibitor |
Direct Interaction | yes |
n/a |
Mechanism of Interaction | Dopamine transporter releasing agent |
Direct Interaction | yes |
inhibitor (inhibitory) |
Trial Name | fexofenadine + ps/ |
Novel drug target | Established target |
inhibitor (inhibitory) |
Mechanism of Interaction | Monoamine transporter inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Dopamine transporter inhibitor |
Direct Interaction | yes |
Trial Name | Lu AA24530 |
SLC6A3 | Ensembl Gene Name |
Gene Biotype | PROTEIN_CODING |
SLC6A3 | Uniprot Gene Name |
Q01959 | Uniprot Accession |
SODIUM-DEPENDENT DOPAMINE TRANSPORTER | Uniprot Protein Name |
Uniprot Status | Swiss-Prot |
Interpro Name | Sodium:neurotransmitter symporter |
Interpro Acc | IPR000175 |
TRANSPORTER, DRUGGABLE GENOME |
SLC6A3 | Display Id |
SODIUM-DEPENDENT DOPAMINE TRANSPORTER (DA TRANSPORTER) (DAT). [SOURCE:UNIPROT/SWISSPROT;ACC:Q01959] | Description |
ENSG00000142319 | Ensembl Gene Id |
Human Readable Name | DRUGGABLE GENOME |
DRUGGABLE GENOME |
Q01959 | Uniprot Accession |
SC6A3_HUMAN | Uniprot Id |
SLC6A3 | Gene Symbol |
Target Subclass | SLC |
Transmembrane Helix Count | 12 |
Target Subclass | SLC6 |
SLC6A3 | Gene Symbol |
Target Class | Transporters |
Target Subclass | TC:2.A.22.1.3 |
PA311 | PharmGKB ID |
DAT1 | GENE_SYMBOL |
SLC6A3 | GENE_SYMBOL |
Sodium-dependent dopamine transporter | UNIPROT |
ENSG00000142319 | Gene Symbol |
SLC6A3 | Ensembl Id |
DRUGGABLE GENOME |
DAT1 | GO Gene Synonym |
CELL SURFACE |
DAT | TTD Gene Abbreviation |
T55959 | TTD Target ID |
Sodium-dependent dopamine transporter | Gene Name |
Q01959 | UniProt ID |
TRANSPORTER |